Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “unicorn” status secured a ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...